Validating and creating a short-form of the persisting effects questionnaire: A measure of positive and negative outcomes from psychedelic experiences

Paper. Ehrenkranz R, Sepeda ND, Goldy SP et al.. Journal of Psychopharmacology, 18 Sep 2026.

Weekly Science Digest, 19 Sep 2026 to 25 Sep 2026, finding 5: In brief

the Persisting Effects Questionnaire fails to replicate its assumed factor structure; authors offer a validated two-factor short form

Weekly Science Digest, 12 Sep 2026 to 18 Sep 2026, finding 3: The field auditing its own tools

Three papers go after blinding, the word "plasticity", and the main outcomes scale.

A JAMA Psychiatry viewpoint proposes UMBRAA — unidentifiable multidrug blinding with reduced, authorized awareness — to attack the masking problem head-on. Carhart-Harris and colleagues argue that popular neuroplasticity biomarkers often index canalization, the opposite of plasticity proper. And the Persisting Effects Questionnaire, used for decades, turns out not to support its assumed factor structure: it collapses to positive and negative, now with a validated short form.

Read the original

—
Node—
Statuslive
Throughput—